TUCSON, Ariz., September 30, 2024 — Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.Continue reading
Category Archives: AZBio News
Application for the Class of 2025 Termeer Fellowship is now open!
This is a unique opportunity for first-time biotech and life science CEOs to join an inclusive and empowering community dedicated to developing the next generation of leaders who are shaping the future of healthcare.Continue reading
Do You Have a Session Idea for BIO 2025?
The submission deadline is October 17, 2024.
Download the 2025 Submission Guide.
Individuals whose proposals have been selected will be notified mid-January 2025.Continue reading
NIH Launches Redesigned Grants and Funding Website
NIH launched the new NIH Grants and Funding website in September. Designed with the needs of the extramural research community in mind, the new site is intended to enhance your journey through the NIH grants process with a modernized interface and powerful features to make finding critical information easier than ever.
A key change involves a redesign of the NIH Guide for Grants and Contracts and related funding information. The new tools reduce reliance on activity codes and other NIH jargon to help you explore opportunities for funding in a more intuitive way.Continue reading
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies
Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms
The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia
Continue reading
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) — Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane Award from the Arizona Bioindustry Association (AZBio). Each year a select group of Arizona-based life science companies are recognized for the progress they are making to develop and deliver health innovations. Nectero Medical accepted the award at the 20th Annual AZBio Awards Dinner held on Wednesday, September 18th at the Phoenix Convention Center as part of Arizona Bioscience Week, which is presented by AZBio and the Arizona Commerce Authority.Continue reading
Phoenix-Based Nonprofit, Focus on Lyme – Breakthrough in Lyme Disease Testing: New Diagnostic Tool Boasts Over 90% Accuracy
Focus on Lyme and Tulane University License Groundbreaking Diagnostic Technology to Aces Diagnostics Inc.Continue reading
Stephenson Prize for Innovation in Pancreatic Cancer Research Launched With $150 Million Gift to City of Hope
LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, has received a historic $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and his daughter Tessa Stephenson Brand to immediately fund pancreatic cancer research. Continue reading